Radiochemical Purity of 68Ga-BCA-Peptides: Separation of All 68Ga Species with a Single iTLC Strip

Authors: Anton A. Larenkov, Alesya Ya Maruk

Abstract:

In the present study, highly effective iTLC single strip method for the determination of radiochemical purity (RCP) of ⁶⁸Ga-BCA-peptides was developed (with no double-developing, changing of eluents or other additional manipulation). In this method iTLC-SG strips and commonly used eluent TFA_aq. (3-5 % (v/v)) are used. The method allows determining each of the key radiochemical forms of ⁶⁸Ga (colloidal, bound, ionic) separately with the peaks separation being no less than 4 σ. Rf = 0.0-0.1 for ⁶⁸Ga-colloid; Rf = 0.5-0.6 for ⁶⁸Ga-BCA-peptides; Rf = 0.9-1.0 for ionic ⁶⁸Ga. The method is simple and fast: For developing length of 75 mm only 4-6 min is required (versus 18-20 min for pharmacopoeial method). The method has been tested on various compounds (including ⁶⁸Ga-DOTA-TOC, ⁶⁸Ga-DOTA-TATE, ⁶⁸Ga-NODAGA-RGD₂ etc.). The cross-validation work for every specific form of ⁶⁸Ga showed good correlation between method developed and control (pharmacopoeial) methods. The method can become convenient and much more informative replacement for pharmacopoeial methods, including HPLC.

Keywords: DOTA-TATE, 68Ga, quality control, radiochemical purity, radiopharmaceuticals, iTLC.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1126784

References:

[1] European Directorate for the Quality of Medicines & Healthcare (EDQM). Gallium (68Ga) edotreotide injection. European Pharmacopoeia 8.0. 01/2013:2482:4847–48.
[2] Eidherr, H., Girschele, F., Mitterhauser, M. and Wadsak, W. Synthesis of (68Ga)Gallium Dota-(Tyr3)-Octreotide Acetate ((68Ga)-Dotatoc) (2012) p.321-332, in Radiochemical Syntheses: Radiopharmaceuticals for Positron Emission Tomography, Volume 1 (eds. P. J. H. Scott and B. G. Hockley), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi:10.1002/9781118140345.ch32.
[3] Mukherjee A., Pandey U., Chakravarty R., Sarma H.D., Dash A. Single vial kit formulation for preparation of PET radiopharmaceutical: 68Ga-DOTA-TOC. J Radioanal Nucl Chem (2014) 302:1253–1258, doi:10.1007/s10967-014-3643-7.
[4] Blom E., Koziorowski J. 68Ga-Autoclabeling of DOTA-TATE and DOTA-NOC. Appl Radiat Isot (2012) 70:980-983, doi:10.1016/j.apradiso.2012.03.032.
[5] Ali M., Hsieh W. and Tsopelas C. An improved assay for 68Ga-hydroxide in 68Ga-DOTATATE formulations intended for neuroendocrine tumour imaging. J Label Compd Radiopharm (2015) 58:383–389, doi:10.1002/jlcr.3318.
[6] Aslani A, Snowdon GM, Bailey DL, Schembri GP, Bailey EA, Roach PJ. Gallium‐68 DOTATATE Production with Automated PET Radiopharmaceutical Synthesis System: A Three Year Experience. Asia Oceania J Nucl Med Biol (2014) 2(2):75‐86.
[7] Larenkov A. A., Bruskin A. B. and Kodina G. E. Preparation of High-Purity 68Ga Solutions by Ion Exchange in Mixed Acetone–Hydrochloric Acid Medium. Radiochemistry (2014) 56:57–65, doi:10.1134/S1066362214010123.
[8] Larenkov A. A., Bruskin A. B. and Kodina G. E. Preparation of highly purified 68Ga solutions via ion exchange in hydrochloric acid–ethanol mixtures. J Radioanal Nucl Chem (2015) 305:147-160, doi:10.1007/s10967-015-4089-2.
[9] Schultz M., Mueller D., Baum R., Watkins G., Breeman W. A new automated NaCl based robust method for routine production of gallium-68 labeled peptides. Appl Radiat Isot (2013) 76:46-54, doi:10.1016/j.apradiso.2012.08.011.
[10] Ocak M., Antretter M., Knopp R., Kunkel F., Petrik M., Bergisadi N., Decristoforo C. Full automation of 68Ga labelling of DOTA-peptides including cation exchange prepurification. Appl Radiat Isot (2010) 68:297–302, doi:10.1016/j.apradiso.2009.10.006.
[11] Baur B., Solbach C., Andreolli E., Winter G., Machulla H.-J., Reske S.N. Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep. Pharmaceuticals (2014) 7:517-529, doi:10.3390/ph7050517.
[12] Sharma V., Prior J.L., Belinsky M.G., Kruh G.D. and Piwnica-Worms D. Characterization of a 67Ga/68Ga Radiopharmaceutical for SPECT and PET of MDR1 P-Glycoprotein Transport Activity In Vivo: Validation in Multidrug-Resistant Tumors and at the Blood–Brain Barrier. J Nucl Med (2005) 46:354 –364.
[13] Vis R., Lavalaye J., van de Garde E.M.W. GMP-compliant 68Ga radiolabelling in a conventional small-scale radiopharmacy: a feasible approach for routine clinical use. EJNMMI Research (2015) 5:27, doi:10.1186/s13550-015-0105-3.
[14] Aghanejad A., Jalilian A.R., Maus S., Yousefnia H., Geramifar P., Beiki D. Optimized production and quality control of 68Ga-DOTATATE. Iran J Nucl Med (2016) 24:29-36.
[15] Banerjee S.R., Chen Z., Pullambhatla M., Lisok A., Chen J., Mease R.C. and Pomper M.G. Preclinical Comparative Study of 68Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA. Bioconjugate Chemistry (2016) 27(6):1447-1455, doi:10.1021/acs.bioconjchem.5b00679.
[16] Eder M., Neels O., Müller M., Bauder-Wüst U., Remde Y., Schäfer M., Hennrich U., Eisenhut M., Afshar-Oromieh A., Haberkorn U., Kopka K. Novel Preclinical and Radiopharmaceutical Aspects of (68Ga)Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. Pharmaceuticals (2014) 7:779-796, doi:10.3390/ph7070779.
[17] Zoghi M., Jalilian A.R., Niazi A., Johari-Daha F., Alirezapour B., Ramezanpour S. Development of a 68Ga-peptide tracer for PET GnRH1-imaging. Ann Nucl Med (2016) 30(6):400-8, doi:10.1007/s12149-016-1074-y.
[18] European Directorate for the Quality of Medicines & Healthcare (EDQM). Radiopharmaceutical preparations. European Pharmacopoeia 8.0. 01/2014:0125:759-63.